DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Evofosfamide
Evofosfamide
Exploiting the Cancer Niche: Tumor-Associated Macrophages and Hypoxia As Promising Synergistic Targets for Nano-Based Therapy
Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
Sarcoma Field Digests Evofosfamide Failure
Evofosfamide for Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer – First Line in Combination with Gemcitabine
Management of Metastatic Pancreatic Adenocarcinoma
Preclinical Benefit of Hypoxia-Activated Intra- Arterial
WO 2017/095805 Al 8 June 2017 (08.06.2017) W P O P C T
Targeting Hypoxic Habitats with Hypoxia Pro-Drug Evofosfamide in Preclinical Models of Sarcoma
A Phase 1/2 Study of Evofosfamide, a Hypoxia-Activated Prodrug with Or Without Bortezomib 2 in Subjects with Relapsed/Refractory Multiple Myeloma 3
Chemotherapy in NEN: Still Has a Role?
Phase IB Study of Sorafenib and Evofosfamide in Patients with Advanced Hepatocellular and Renal Cell Carcinomas (NCCTG N1135, Alliance)
New Cancer Therapies for the 21St Century: a Two Decade Review Of
Targeting the Hypoxic Fraction of Tumours Using Hypoxia-Activated
The Hypoxia-Activated Prodrug Evofosfamide in Combination with Multiple Regimens of Radiotherapy
Multi-Discipline Review
Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors
Download of These Slides, Please Direct Your Browser to the Following Web Address
Nab-Paclitaxel for the Treatment of Pancreatic Cancer Open Access to Scientific and Medical Research DOI
Top View
Phase Ib Dose-Escalation Study of the Hypoxia-Modifier Myo-Inositol
Identification of P450 Oxidoreductase As a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs
Bioactive Compound Library Plus (96-Well)
1078-0432.CCR-15-1853.Full-Text.Pdf
Administration of Hypoxia-Activated Prodrug Evofosfamide After
Targeting Cancer
Phase I Clinical Trials VOLUME 14, NO
A Phase I/II Study of Evofosfamide, a Hypoxia-Activated Prodrug with Or Without Bortezomib in Subjects with Relapsed/ Refractory Multiple Myeloma Jacob P
Evofosfamide Is Effective Against Pediatric Aggressive Glioma Cell
TH-302) in Rodent Glioma Models
Applications of Evolutionary Modeling to the Study of Drug Resistance in Cancer
Theranostics Deep-Learning and MR Images to Target Hypoxic Habitats
Complex Roles of the Stroma in the Intrinsic Resistance to Gemcitabine in Pancreatic Cancer: Where We Are and Wherewearegoing
Negative Head and Neck Squamous Cell Carcinoma
And Mtor Inhibitors Results in Enhanced Antitumor Efficacy in Preclinical Renal Cell Carcinoma Models